Condition: Early Readmission to the ICU · Sponsor: Société Française d'Anesthésie et de Réanimation
The COVID-19 health crisis has highlighted pre-existing challenges in patient flow management within healthcare facilities, especially in critical care units. This has sparked debate regarding the sufficiency of critical care beds in France, while drawing attention to the lack of downstream structures. Inefficient patient flow, leading to bed occupancy bottlenecks, has been correlated with both critical care length of stay and morbidity. Unplanned early readmission to critical care further exacerbates these strains and prolongs hospital length of stay. Currently, no standardized criteria are available to guide safe discharge from critical care. A recent Delphi consensus study proposed a set of criteria, although largely subjective. The primary outcome of the present study is to identify factors associated with unplanned early readmission to critical care within 48 hours of discharge. Delayed discharge from critical care represents another major bottleneck contributing to system strain. The secondary outcome of this study is therefore to assess the proportion of critical care beds occupied by patients deemed ready for discharge by the medical team, as well as to analyze the reasons underlying such delayed transfers.
This description comes directly from the study's public registry record.
Merlin DELOURME,, MD · +33 1 42 49 93 94 · merlin.delourme@aphp.fr
François DEPRET · +33 1 42 49 93 94 · francois.depret@aphp.fr
Always discuss trial participation with your own doctor first.
| Hôpital Saint-Louis, AP-HP | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07182916